scholarly journals Clinicopathologic characteristics and survival outcomes of patients with advanced esophageal, gastroesophageal junction, and gastric adenocarcinoma: a single-institution experience

2012 ◽  
Vol 19 (6) ◽  
Author(s):  
A. Dechaphunkul ◽  
K. Mulder ◽  
F. El-Gehani ◽  
S. Ghosh ◽  
J. Deschenes ◽  
...  
Keyword(s):  
Gastric Adenocarcinoma ◽  
Gastroesophageal Junction ◽  
Survival Outcomes ◽  
Single Institution ◽  
Clinicopathologic Characteristics

scholarly journals Expression of BAFF and BAFF-R in Follicular Lymphoma: Correlation with Clinicopathologic Characteristics and Survival Outcomes

PLoS ONE ◽  
2012 ◽  
Vol 7 (12) ◽  
pp. e50936 ◽  
Author(s):  
Ya-Jun Li ◽  
Wen-Qi Jiang ◽  
Hui-Lan Rao ◽  
Jia-Jia Huang ◽  
Yi Xia ◽  
...  
Keyword(s):  
Follicular Lymphoma ◽  
Survival Outcomes ◽  
Clinicopathologic Characteristics

scholarly journals Gastric Carcinoma with Osteoclast-Like Giant Cells Coexisting with Gastrointestinal Spindle Cell Tumor

2013 ◽  
Vol 2013 ◽  
pp. 1-4 ◽  
Author(s):  
Christos Poulios ◽  
Triantafyllia Koletsa ◽  
Antonis Goulas ◽  
Georgia Karayannopoulou ◽  
Eleni Vrettou ◽  
...  
Keyword(s):  
Gastric Adenocarcinoma ◽  
Spindle Cell ◽  
Gastroesophageal Junction ◽  
Subtotal Gastrectomy ◽  
Giant Cells ◽  
Gastric Fundus ◽  
Gastric Carcinomas ◽  
Spindle Cell Lesion ◽  
Exophytic Tumor ◽  
Upper Abdominal

Reactive multinucleated osteoclast-like giant cells (OGCs) have been described in a variety of neoplasms but rarely in gastric carcinomas. Reported herein is a case of an 81-year-old Caucasian male presented with upper abdominal pain and dysphagia. Esophagogastroscopy revealed an ulcerative mass and a specimen of subtotal gastrectomy and lower esophagectomy was sent for histologic examination. At the gastroesophageal junction an exophytic tumor, measured 2.2 cm in greatest diameter, was observed. Sections from the tumor showed gastric adenocarcinoma, stage pT1bpN0. Diffusely among the neoplastic cells multinucleated giant cells, resembling osteoclasts, were observed, which were positive for CD68, lysozyme, and vimentin and negative for AE1/AE3, CK8/18, hHCG, and LMP1. Moreover, in a random section from the gastric fundus, a spindle cell lesion, sized 0.6 cm, was revealed, which was positive for CD117 and CD34 antigens and was diagnosed as gastrointestinal stromal tumor (GIST). The presence of OGCs is an uncommon finding in gastric carcinomas and by analogy to breast and pancreatic carcinomas it could characterize a rare distinct morphological variant of gastric adenocarcinoma. Due to the limited number of the reported cases, the prognostic value of OGCs is under discussion. Furthermore, pathologists should be aware that incidental GIST may accompany any tumor.

Pancreatic Acinar Metaplasia at the Gastroesophageal Junction: A Single Institution Experience

2015 ◽  
Vol 110 ◽  
pp. S735
Author(s):  
Nicolas A. Villa ◽  
Dora Lam-Himlin ◽  
Rahul Pannala ◽  
David E. Fleischer ◽  
Francisco C. Ramirez ◽  
...  
Keyword(s):  
Gastroesophageal Junction ◽  
Single Institution ◽  
Pancreatic Acinar Metaplasia

Seventh edition (2010) of gastric adenocarcinoma AJCC staging system: Is there room for improvement?

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 77-77
Author(s):  
Manali I. Patel ◽  
Kim F Rhoads ◽  
Yifei Ma ◽  
James M. Ford ◽  
Jeffrey A. Norton ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Gastric Adenocarcinoma ◽  
Health Planning ◽  
Gastroesophageal Junction ◽  
Staging System ◽  
Rank Test ◽  
Population Database ◽  
Curative Intent ◽  
Ajcc Staging System ◽  
Ajcc Staging

77 Background: The gastric cancer AJCC staging system recently underwent significant modifications of the T and N categories as well as stage groupings. The new system has not been validated on a US population database, but studies on Asian patients have reported no difference in survival between stages IB and IIA, as well as IIB and IIIA. Methods: California Cancer Registry data linked to Office of Statewide Health Planning and Development discharge abstracts were used to identify patients with gastric adenocarcinoma (gastroesophageal junction tumors excluded) who underwent curative-intent surgical resection from 2002 to 2006. AJCC stage was reclassified based on the 7th edition. Disease-specific survival (DSS) probabilities were calculated using the Kaplan-Meier method and compared using the log rank test. Results: Of 4,985 patients identified, 2,262 had complete pathologic data and known cause of death. Median age was 70 years and 60% were males. Median number of examined lymph nodes was 12 and 39% of patients received adjuvant chemotherapy. The 7th edition AJCC system did not distinguish outcome adequately between stages IB and IIA (P = .25), or IIB and IIIA (P = .33, Table ). By merging stage II into one category and moving T2N1 to stage IB and T2N2, T1N3 to stage IIIA, we propose a new grouping system which showed improved discriminatory ability ( Table ). Conclusions: In this first study validating the new 7th edition AJCC staging system for gastric cancer on a US population, we found stages IB and IIA, as well as IIB and IIIA to perform similarly. We propose a revised stage grouping for the AJCC system that better discriminates between outcomes. [Table: see text]

Survival outcomes for de novo versus relapsed stage IV gastric and gastroesophageal junction (GEJ) adenocarcinoma.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 148-148
Author(s):  
Bryan Anthony Chan ◽  
Hao-Wen Sim ◽  
Akina Natori ◽  
Stephanie Moignard ◽  
Daniel Yokom ◽  
...  
Keyword(s):  
Proportional Hazards ◽  
De Novo ◽  
Performance Status ◽  
Gastroesophageal Junction ◽  
Tumor Biology ◽  
Stage Iv ◽  
Cox Proportional Hazards ◽  
Survival Outcomes ◽  
Primary Therapy ◽  
Metastatic Relapse

148 Background: In gastric/GEJ cancer, 40% of patients (pts) are metastatic at diagnosis ( de novo stage IV) and up to 70% with locoregional disease recur (relapsed stage IV). We compared survival outcomes between de novo vs relapsed stage IV. Methods: A retrospective observational study of stage IV gastric/GEJ pts was conducted (2012-2015). Overall survival (OS) was from date of stage IV diagnosis. PFS1 defined the period from stage IV diagnosis to first progression. PFS2 was from first to second progression. For relapsed stage IV pts, disease-free interval (DFI) was the period from initial diagnosis to metastatic relapse. Cox proportional hazards models compared OS, PFS1 and PFS2 between de novo vs relapsed stage IV pts, stratified by DFI [ < 6, 6-12 and > 12 months (mo)] and controlled for baseline patient characteristics. Results: Of 198 pts, 62% were male and median age was 64 years (26-93), with 64% gastric and 36% GEJ adenocarcinomas. Primary therapy for locoregional pts included surgery (75%), perioperative chemotherapy (42%) and radiotherapy (42%). De novo and relapsed stage IV pts represented 68% and 32% of the cohort respectively. Median follow-up was 13 mo. Controlled for age, performance status and Charlson comorbidity index, there were no significant differences in OS (median OS 12.5 ( de novo) vs 12.2 mo (relapsed); HR 1.22, 95% CI 0.83-1.77, p = 0.31), PFS1 (6.8 vs 7.4 mo; HR 1.00, 95% CI 0.65-1.56, p = 0.98) or PFS2 (3.8 vs 3.0 mo; HR 1.03, 95% CI 0.44-2.41, p = 0.95). Median OS for relapsed stage IV patients were different by DFI groups (log-rank p = 0.02): 22.9 mo (for DFI > 12mo; n = 31), 11.2 mo (DFI 6-12; n = 19) and 7.5 mo (DFI < 6; n = 14). Additionally, OS was significantly better if the DFI was greater than 12 mo, compared with de novo stage IV (HR 0.50, 95% CI 0.28-0.88, p = 0.02). Conclusions: There was no observed difference in the natural history of de novo vs relapsed stage IV gastric/GEJ pts. DFI was strongly prognostic with median OS (from date of relapse) approaching 2 years for relapsed pts with DFI > 12 mo. In addition to implications for treatment strategy, tumor biology within subgroups should be examined to identify novel biomarkers and potential therapeutic targets.

Sign in / Sign up

Export Citation Format

Share Document